V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog (KIT) Antikörper (PE)

Antigen: V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog (KIT)

Synonyme: PBT, SCFR, C-Kit, CD117, W, Bs, Fdc, Ssm, SCO1, SCO5, SOW3, c-KIT, Tr-kit, Gsfsco1, Gsfsco5, Gsfsow3, c-kit, kit-A, XKrk1, KIT, MGF, LOC100221238, C-KIT

Klonalität: Monoklonal (95C3)

Wirt: Maus

Reaktivität: Human

Konjugat: PE

Applikation: Durchflusszytometrie (FACS), Immunfluoreszenz (IF)

Produktnummer: ABIN132133

Produktbeschreibung

Weitere Bezeichnung: CD117 (SCF Receptor, c-kit)

Format: Purified

Isotyp: IgG1

Klon: 95C3

Spezifität: The epitope recognized by antibody 95C3 is expressed by hematopoietic progenitor cells and mast cells. The CD117 mAb (clone 95C3) recognizes stem cell factor, also termed c-kit, steel factor receptor or mast cell growth factor.

Anwendungen

Applikationshinweise: The 95C3 antibody permits the identification and enumeration of human hematopoietic progentor cells and mast cells using flow cytometry. Results must be put within the context of other diagnostic tests as well as the clinical history of the patient by a certified professional before final interpretation. Analyses performed with this antibody should be paralleled by positive and negative controls. If unexpected results are obtained which cannot be attributed to differences in laboratory procedures, please contact us. Samples: Biological fluids (blood, bone marrow, and others) must be collected under sterile conditions. Anticoagulation with EDTA or heparin is recommended. The samples should be stored at room temperature until used. For optimal results, samples should be processed and analyzed within 24 hours. Samples with high numbers of non-viable cells might cause false results, such cases require determination of cell viability with e.g. propidium iodide. All biological samples have to be handled with caution. Always consider them as potentially infective. Use appropriate precautions such as gloves, lab-coat, etc. Sensitivity: The sensitivity of 95C3 mAb is determined by staining welldefined blood samples from representative donors with serialfold mAb dilutions to obtain a titration curve that allows relating the mAb concentration to the percentage of stained cells and geometric MFI (mean fluorescence intensity). For this purpose, a mAb-concentration range is selected to include both the saturation point (i.e. the mAb dilution expected to bind all epitopes on the target cell) and the detection threshold (i.e. the mAb dilution expected to represent the least amount of mAb needed to detect an identical percentage of cells). In practice, 50 ?l of leukocytes containing 107cells/ml are stained with 20 ?l mAb of various dilutions to obtain a titration curve and to identify the saturation point and detection threshold. The final concentration of the product is then adjusted to be at least 3-fold above the detection threshold. In addition and to control lot-to-lot variation, the given lot is compared and adjusted to fluorescence standards with defined intensity.

Reinigung: Chromatography

Buffer: PBS pH 7.2, 1% BSA, 0.05% NaN3

Lagerung: For stability reasons this monoclonal antibody solution contains sodium azide. These reagents should be stored at 2-8

Beschränkungen: Für Forschungszwecke. Als CE-zertifizierter Antikörper in der Europäischen Union für In Vitro Diagnostik (IVD) zugelassen.

Bilder

anti-V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog (KIT) antibody (PE)

Publikationen

Publikationen: Bischoff, Dahinden: "c-kit ligand: a unique potentiator of mediator release by human lung mast cells." in: The Journal of experimental medicine, Vol. 175, Issue 1, pp. 237-44, 1992 (PubMed).

Strobl, Takimoto, Majdic et al.: "Antigenic analysis of human haemopoietic progenitor cells expressing the growth factor receptor c-kit." in: British journal of haematology, Vol. 82, Issue 2, pp. 287-94, 1992 (PubMed).

Strohmeyer, Peter, Hartmann et al.: "Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors." in: Cancer research, Vol. 51, Issue 7, pp. 1811-6, 1991 (PubMed).

Ashman, Cambareri, To et al.: "Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow." in: Blood, Vol. 78, Issue 1, pp. 30-7, 1991 (PubMed).

Papayannopoulou, Brice, Broudy et al.: "Isolation of c-kit receptor-expressing cells from bone marrow, peripheral blood, and fetal liver: functional properties and composite antigenic profile." in: Blood, Vol. 78, Issue 6, pp. 1403-12, 1991 (PubMed).

Carow, Hangoc, Cooper et al.: "Mast cell growth factor (c-kit ligand) supports the growth of human multipotential progenitor cells with a high replating potential." in: Blood, Vol. 78, Issue 9, pp. 2216-21, 1991 (PubMed).

Buehring, Ullrich, Schaudt et al.: "The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 5, Issue 10, pp. 854-60, 1992 (PubMed).

Sillaber, Strobl, Bevec et al.: "IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 147, Issue 12, pp. 4224-8, 1992 (PubMed).

Majumder, Brown, Qiu et al.: "c-kit protein, a transmembrane kinase: identification in tissues and characterization." in: Molecular and cellular biology, Vol. 8, Issue 11, pp. 4896-903, 1989 (PubMed).

Wang, Curtis, Geissler et al.: "The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 3, Issue 10, pp. 699-702, 1989 (PubMed).

Ashman, Roberts, Gadd et al.: "Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia." in: Leukemia research, Vol. 12, Issue 11-12, pp. 923-8, 1989 (PubMed).

Buehring, Herbst, Kostka et al.: "Modulation of p145c-kit function in cells of patients with acute myeloblastic leukemia." in: Cancer research, Vol. 53, Issue 18, pp. 4424-31, 1993 (PubMed).

Bene, Bernier, Casasnovas et al.: "The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL)." in: Blood, Vol. 92, Issue 2, pp. 596-9, 1998 (PubMed).

Nomdedeu, Mateu, Altes et al.: "Enhanced myeloid specificity of CD117 compared with CD13 and CD33." in: Leukemia research, Vol. 23, Issue 4, pp. 341-7, 1999 (PubMed).

Scolnik, Morilla, de Bracco et al.: "CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease." in: Leukemia research, Vol. 26, Issue 7, pp. 615-9, 2002 (PubMed).

Casasnovas, Slimane, Garand et al.: "Immunological classification of acute myeloblastic leukemias: relevance to patient outcome." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 17, Issue 3, pp. 515-27, 2003 (PubMed).

Wagner, Alexander: "Of kit and mouse and man." in: Current biology : CB, Vol. 1, Issue 6, pp. 356-8, 2004 (PubMed).

Chilton-Macneill, Ho, Hawkins et al.: "C-kit expression and mutational analysis in medulloblastoma." in: Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, Vol. 7, Issue 5, pp. 493-8, 2004 (PubMed).

Tavil, Cetin, Tuncer: "CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome." in: Leukemia research, Vol. 30, Issue 2, pp. 222-4, 2005 (PubMed).

B: "MSG: A 20-Year Debate Continues." in: Science (New York, N.Y.), Vol. 247, Issue 4938, pp. 21, 2007 (PubMed).